Antiarrhythmic Drugs

  • E. M. Vaughan Williams

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 89)

Table of contents

  1. Front Matter
    Pages I-XXVIII
  2. Introduction

    1. Front Matter
      Pages N1-N1
    2. E. M. Vaughan Williams
      Pages 1-43
    3. E. M. Vaughan Williams
      Pages 45-67
    4. E. N. Moore, J. F. Spear
      Pages 69-85
    5. P. Coumel
      Pages 87-103
    6. D. G. Julian, J. C. Cowan
      Pages 105-120
  3. Antiarrhythmic Therapy

    1. Front Matter
      Pages N2-N2
    2. Class I Agents

      1. T. J. Campbell
        Pages 175-199
      2. D. W. G. Harron, R. G. Shanks
        Pages 201-233
      3. J. C. Somberg
        Pages 235-277
    3. Class II Agents

    4. Class III Agents

      1. S. B. Olsson
        Pages 323-334
      2. S. M. Cobbe
        Pages 365-387
      3. M. I. Steinberg, J. K. Smallwood
        Pages 389-412
    5. Class IV Agents

    6. Class V Agents

      1. W. Kobinger
        Pages 423-452
    7. Other Therapies

      1. P. Puech, A. Munoz, A. Sassine, J. Brugada
        Pages 453-460
      2. A. J. Camm, D. W. Davies
        Pages 465-474
  4. Factors Involved in Arrhythmogenesis

  5. Epilogue

    1. E. M. Vaughan Williams
      Pages 641-642
  6. Back Matter
    Pages 643-650

About this book


The development of a new antiarrhythmic drug involves many people with disparate skills. The organic chemist who makes it is guided not only by the structure-action relations of previous compounds, but by anticipation of a requirement for a particular type of action. In fact several of the best-known antiarrhythmics, including lidocaine, mexiletine, amiodarone and verapamil, were originally synthesized for other purposes. Physicians have to determine whether the new drug works, and pharma­ cologists how it works. For some years I have believed that there was room for a work which could be understood by all these groups and which could enlighten each about the point of view of the others. Thus when I was invited by Springer-Verlag to prepare a volume in their series Handbook of Experimental Pharmacology, I already had a firm conception of what its form should be. In any multi-author work there are two objectives which cannot always readily be reconciled. The first is to select topics which would relate to each other in a coherent manner. to give a logical and orderly shape to the volume as a whole. The second is to offer authors the greatest possible freedom to express themselves as they wish. When the general design was complete, prospective contributors were invited to write specific chapters, being provided with a complete list of their coauthors and chosen topics, so that they could avoid overlap.


drug electrophysiology pharmacology physiology receptor

Editors and affiliations

  • E. M. Vaughan Williams
    • 1
  1. 1.Hertford CollegeOxford UniversityOxfordGreat Britain

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1989
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-73668-1
  • Online ISBN 978-3-642-73666-7
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods